We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
+32.81%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$123M
AUM Growth
+$23M
Cap. Flow
-$4.05M
Cap. Flow %
-3.28%
Top 10 Hldgs %
69.68%
Holding
33
New
6
Increased
7
Reduced
12
Closed
7

Top Buys

Rank Stock Value
1
AGIO icon
Agios Pharmaceuticals
AGIO
+$4.13M
2
EVH icon
Evolent Health
EVH
+$3.4M
3
EXAS
Exact Sciences
EXAS
+$2.73M
4
MDRX
Veradigm Inc. Common Stock
MDRX
+$2.67M
5
GHDX
Genomic Health, Inc.
GHDX
+$2.51M

Top Sells

Rank Stock Value
1
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$3.98M
2
GBT
Global Blood Therapeutics, Inc.
GBT
+$3.62M
3
BLUE
bluebird bio
BLUE
+$3.5M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$2.36M
5
AVXS
AveXis, Inc. Common Stock
AVXS
+$1.71M

Sector Composition

Rank Sector Weight
1 Healthcare 82.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AGIO icon
1
Agios Pharmaceuticals
AGIO
$1.82B
$14.9M 12.08%
282,443
+94,943
+51% +$4.13M
SAGE
2
DELISTED
Sage Therapeutics
SAGE
$12.3M 9.94%
266,500
+38,000
+17% +$1.55M
FMI
3
DELISTED
Foundation Medicine, Inc.
FMI
$9.69M 7.85%
415,000
+25,000
+6% +$568K
EVH icon
4
Evolent Health
EVH
$353M
$9.48M 7.68%
385,000
+145,500
+61% +$3.4M
BPMC
5
DELISTED
Blueprint Medicines
BPMC
$8.52M 6.9%
287,000
-53,000
-16% -$1.32M
LOXO
6
DELISTED
Loxo Oncology, Inc
LOXO
$7.62M 6.17%
291,000
-9,000
-3% -$235K
GNMK
7
DELISTED
GenMark Diagnostics, Inc
GNMK
$7.38M 5.97%
625,000
+210,000
+51% +$2.03M
ONCE
8
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$5.62M 4.55%
93,500
-69,000
-42% -$3.98M
GBT
9
DELISTED
Global Blood Therapeutics, Inc.
GBT
$5.53M 4.48%
240,000
-190,000
-44% -$3.62M
KITE
10
DELISTED
Kite Pharma, Inc.
KITE
$5.03M 4.07%
90,000
+17,500
+24% +$975K
BLUE
11
DELISTED
bluebird bio
BLUE
$4.07M 3.29%
4,632
-4,825
-51% -$3.5M
CLVS
12
DELISTED
Clovis Oncology, Inc.
CLVS
$3.97M 3.21%
110,000
-40,000
-27% -$858K
VYGR icon
13
Voyager Therapeutics
VYGR
$181M
$3.32M 2.69%
276,500
-46,000
-14% -$623K
EPZM
14
DELISTED
Epizyme, Inc
EPZM
$2.9M 2.35%
295,000
-45,000
-13% -$411K
EXAS
15
DELISTED
Exact Sciences
EXAS
$2.88M 2.33%
+155,000
New +$2.73M
ALNY icon
16
Alnylam Pharmaceuticals
ALNY
$29.5B
$2.64M 2.14%
39,000
-33,500
-46% -$2.36M
MDRX
17
DELISTED
Veradigm Inc. Common Stock
MDRX
$2.63M 2.13%
+200,000
New +$2.67M
MYOK
18
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$2.61M 2.12%
160,000
-19,029
-11% -$344K
GHDX
19
DELISTED
Genomic Health, Inc.
GHDX
$2.6M 2.11%
+90,000
New +$2.51M
GNMX
20
DELISTED
Aevi Genomic Medicine Inc
GNMX
$2.09M 1.69%
375,000
+290,000
+341% +$1.65M
CTMX icon
21
CytomX Therapeutics
CTMX
$690M
$2M 1.62%
127,500
-106,679
-46% -$1.29M
IBB icon
22
iShares Biotechnology ETF
IBB
$9.19B
$1.45M 1.17%
+15,000
New +$1.43M
RXDX
23
DELISTED
Ignyta, Inc.
RXDX
$1.23M 0.99%
195,000
-180,000
-48% -$1.05M
IONS icon
24
Ionis Pharmaceuticals
IONS
$9.06B
$1.21M 0.98%
+33,000
New +$1.03M
EDIT icon
25
Editas Medicine
EDIT
$404M
$1.15M 0.93%
+85,470
New +$1.75M
1
2

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
MCM
Mill Capital Management Concord, North Carolina $1.31B AUM 17.4% 1-Year Est. Return
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return
WGAM
Wilkinson Global Asset Management New York $1.31B AUM 17.03% 1-Year Est. Return

Casdin Capital's Q3 2016 Portfolio in Review

As of Q3 2016, Casdin Capital held 33 positions worth $123M, up 23% from $100M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Casdin Capital withdrew a net $4.05M in Q3 2016, closing 7 positions and reducing 12 holdings. Its most notable exit was AveXis, Inc. Common Stock, an estimated $1.71M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 80% a quarter earlier.

Against the trend, Casdin Capital opened a new position in Exact Sciences worth $2.88M.

  • Casdin Capital's largest Q3 2016 buy was Exact Sciences: 155,000 shares worth $2.88M.
  • Casdin Capital added most to Agios Pharmaceuticals in Q3 2016, an estimated $4.13M increase.
  • Casdin Capital's biggest Q3 2016 reduction was Spark Therapeutics, Inc. Common Stock, cutting an estimated $3.98M.
  • Casdin Capital fully exited AveXis, Inc. Common Stock in Q3 2016, selling an estimated $1.71M.
  • Casdin Capital's ten largest holdings make up 70% of its $123M portfolio in Q3 2016.
  • Casdin Capital opened 6 new positions and closed 7 in Q3 2016.
  • Casdin Capital's portfolio value rose 23% quarter-over-quarter to $123M.

Based on Casdin Capital's 13F filing for Q3 2016, filed 14 Nov 2016.